The third-generation inhibitor Osimertinib (OSI, Tagrisso®, AstraZeneca UK Limited, Chesire, England, approved in 2017) has been specifically developed for cancers driven by the T790M EGFR mutation [7]. This evidence concerns the gene EGFR and cancer.